Literature DB >> 24788565

Aberrant expression of CD227 is correlated with tumor characteristics and invasiveness of breast carcinoma.

Ya-Wen Wang1, Duan-Bo Shi, Ya-Min Liu, Yan-Lin Sun, Xu Chen, Shuai Xiang, Qiang Fu, Jun-Min Wei, Peng Gao.   

Abstract

PURPOSE: Increasing evidences demonstrate that CD227 plays a crucial role in the development and progression of breast cancer. However, the function of CD227 in breast carcinoma was still controversial and the investigation on CD227 in Asian race was scarce.
METHODS: To investigate the relationship between CD227 and tumor characteristics of breast carcinoma, CD227, estrogen receptor (ER), progesterone receptor (PR), Her2⁄neu and Ki-67 were detected by immunohistochemistry in a series of 227 patients. The Kaplan-Meier method and log-rank tests were used to estimate the correlation between CD227 expression and patients' prognosis. Furthermore, in vitro invasion assay was performed to examine the effect of CD227 on the invasiveness of breast carcinoma cells after transfection with CD227 cDNA or antisense phosphorothioate oligodeoxynucleotides (ASODN) against CD227 mRNA.
RESULTS: Our data demonstrate that the cytoplasm staining and high expression of CD227 were positively related to the aggressiveness of breast cancer. Both circumferential membrane staining and cytoplasm staining were associated with lymph node metastasis. Moreover, the cytoplasm staining and overexpression of CD227 were found to be related to Her-2/neu positivity, higher Ki-67 positivity and poorer survival of patients. We further demonstrated that the invasion ability of breast carcinoma cells could be enhanced or inhibited by CD227 cDNA or ASODN, respectively.
CONCLUSIONS: We conclude that the aberrant expression of CD227, especially cytoplasm staining could be predictive for tumor aggressiveness, lymph node metastasis, poorer outcome of patients with breast cancers. And CD227 could promote the invasion ability of breast cancer cells, suggesting a potential role of CD227 as an oncogene in breast carcinoma.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24788565     DOI: 10.1007/s00432-014-1676-5

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  32 in total

1.  Expression of MUC1 mucin on activated human T cells: implications for a role of MUC1 in normal immune regulation.

Authors:  B Agrawal; M J Krantz; J Parker; B M Longenecker
Journal:  Cancer Res       Date:  1998-09-15       Impact factor: 12.701

2.  Monoclonal antibody NCRC 11 reactivity with advanced breast carcinoma: lack of prognostic value.

Authors:  C Arnerlöv; I O Ellis; S O Emdin
Journal:  Histopathology       Date:  1988-12       Impact factor: 5.087

Review 3.  Mucins in human neoplasms: clinical pathology, gene expression and diagnostic application.

Authors:  Suguru Yonezawa; Michiyo Higashi; Norishige Yamada; Seiya Yokoyama; Sho Kitamoto; Shinichi Kitajima; Masamichi Goto
Journal:  Pathol Int       Date:  2011-10-25       Impact factor: 2.534

4.  Expression of MUC-1 epitopes on normal bone marrow: implications for the detection of micrometastatic tumor cells.

Authors:  W Brugger; H J Bühring; F Grünebach; W Vogel; S Kaul; R Müller; T H Brümmendorf; B L Ziegler; I Rappold; P Brossart; S Scheding; L Kanz
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

Review 5.  HER2 as a prognostic and predictive marker for breast cancer.

Authors:  T Cooke; J Reeves; A Lanigan; P Stanton
Journal:  Ann Oncol       Date:  2001       Impact factor: 32.976

6.  MUC1 epithelial mucin (CD227) is expressed by activated dendritic cells.

Authors:  M Wykes; K P A MacDonald; M Tran; R J Quin; P X Xing; S J Gendler; D N J Hart; M A McGuckin
Journal:  J Leukoc Biol       Date:  2002-10       Impact factor: 4.962

7.  Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer.

Authors:  Emad A Rakha; Richard W G Boyce; Dalia Abd El-Rehim; Thomas Kurien; Andrew R Green; Emma C Paish; John F R Robertson; Ian O Ellis
Journal:  Mod Pathol       Date:  2005-10       Impact factor: 7.842

8.  MUC1 is activated in a B-cell lymphoma by the t(1;14)(q21;q32) translocation and is rearranged and amplified in B-cell lymphoma subsets.

Authors:  V G Dyomin; N Palanisamy; K O Lloyd; K Dyomina; S C Jhanwar; J Houldsworth; R S Chaganti
Journal:  Blood       Date:  2000-04-15       Impact factor: 22.113

Review 9.  Expression profiles of MUC1, MUC2, and MUC4 mucins in human neoplasms and their relationship with biological behavior.

Authors:  Suguru Yonezawa; Masamichi Goto; Norishige Yamada; Michiyo Higashi; Mitsuharu Nomoto
Journal:  Proteomics       Date:  2008-08       Impact factor: 3.984

10.  MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma.

Authors:  S Nakamori; D M Ota; K R Cleary; K Shirotani; T Irimura
Journal:  Gastroenterology       Date:  1994-02       Impact factor: 22.682

View more
  3 in total

1.  High expression of cAMP-responsive element-binding protein 1 (CREB1) is associated with metastasis, tumor stage and poor outcome in gastric cancer.

Authors:  Ya-Wen Wang; Xu Chen; Ji-Wei Gao; Hui Zhang; Ran-Ran Ma; Zu-Hua Gao; Peng Gao
Journal:  Oncotarget       Date:  2015-04-30

2.  HPV Status and Its Correlation with BCL2, p21, p53, Rb, and Survivin Expression in Breast Cancer in a Chinese Population.

Authors:  Ya-Wen Wang; Kai Zhang; Song Zhao; Yanrong Lv; Jiang Zhu; Huantao Liu; Jinbo Feng; Weili Liang; Rong Ma; Jianli Wang
Journal:  Biomed Res Int       Date:  2017-12-20       Impact factor: 3.411

3.  Overexpression of syndecan-1, MUC-1, and putative stem cell markers in breast cancer leptomeningeal metastasis: a cerebrospinal fluid flow cytometry study.

Authors:  Iole Cordone; Serena Masi; Valentina Summa; Mariantonia Carosi; Antonello Vidiri; Alessandra Fabi; Alessia Pasquale; Laura Conti; Immacolata Rosito; Carmine Maria Carapella; Veronica Villani; Andrea Pace
Journal:  Breast Cancer Res       Date:  2017-04-11       Impact factor: 6.466

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.